Print

IAVI A002

A PHASE 2, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF tgAAC09, AN HIV VACCINE CONTAINING CLADE C Gag-PR-?RT DNA IN AN ADENO-ASSOCIATED VIRUS (AAV) CAPSID, ADMINISTERED TWICE, AT THREE DOSAGE LEVELS AND TWO DOSING INTERVALS

Trial Details:

II Completed
International AIDS Vaccine Initiative (IAVI), Targeted Genetics November 01, 2005
tgAAC09 AAV2 Gag-PR-RT C
tgAAC09 Viral Vector - Adeno-associated Virus
South Africa, Uganda, Zambia 91
NCT00888446
https://clinicaltrials.gov/ct2/show/NCT00888446